Liège, Belgium – An international research team led by scientists from the University of Liège has discovered an interesting new therapeutic target for the treatment of melanoma resistant to targeted therapies. Inhibition of the VARS enzyme could prevent this therapeutic resistance by resensitising tumours resistant to these targeted therapies. Melanoma...
Latest News
London, UK – A new way to classify tuberculosis (TB) that aims to improve focus on the early stages of the disease has been presented by an international team involving researchers at UCL. The new framework, published in The Lancet Respiratory Medicine, seeks to replace the approach of the last...
Houston, Texas – Researchers at Baylor College of Medicine, University of Veterinary Medicine in Austria and Josep Carreras Leukemia Research Institute in Spain discovered that AML cells prevent the synthesis of proteins that suppress their growth by forcibly isolating the mRNAs that encode such proteins within structures known as P-bodies....
Houston, TX – Researchers at The University of Texas MD Anderson Cancer Center showed that altering the sequence of breast cancer treatment to administer radiation before mastectomy allowed for concurrent breast reconstruction surgery, which reduced the number of operations required, minimized treatment delays and improved patient satisfaction. The Phase II...
Oxford, UK – A new paper in JNCI Cancer Spectrum, published by Oxford University Press, finds that following a healthy diet lowers the risk of cardiovascular disease in breast cancer survivors. Cardiovascular disease is the top non-breast cancer related cause of death in women with breast cancer. There are more...
Uppsala, Sweden – Adults who sleep only three to five hours a day are at higher risk of developing type 2 diabetes. This is demonstrated in a new study from Uppsala University, published in JAMA Network Open. It also shows that chronic sleep deprivation cannot be compensated by healthy eating...
MENLO PARK, Calif. & GENEVA, Switzerland — AN2 Therapeutics, Inc. (Nasdaq: ANTX) and the non-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) today announced a collaboration to advance clinical development of AN2-502998, AN2’s oral drug candidate in development for the treatment of chronic Chagas disease. Chagas disease is...
MENLO PARK, Calif. — AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that company management will participate in two upcoming investor conferences in November. Stifel 2023 Healthcare Conference Eric Easom, Co-Founder, President...
Anacor Pharmaceuticals, a biopharmaceutical company engaged in the development of small molecule drugs, has entered into a licensing and research agreement with not-for-profit Global Alliance for TB Drug Development or TB Alliance to explore a novel anti-bacterial drug target for use in tuberculosis therapy. Under the agreement, Anacor will provide...
NEW YORK, NY – A Ludwig Cancer Research study has generated a granular portrait of how the cellular and molecular components of the blood vessels that feed brain metastases of melanoma and lung and breast cancers differ from those of healthy brain tissue, illuminating how they help shape the internal...